Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SLV308 adjunctive therapy dose-escalation study in advanced Parkinson's disease
2005-002432-10Phase 3Terminated
- Sponsor
- Solvay
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Parkinson's disease (PD) comparing SLV308 adjunctive to levodopa with Placebo adjunctive to levodopa (2 arms). Primary endpoint: Dropout rate related to SLV308 dose. Started Oct 2005; status: terminated.
02
Drugs
pardoprunox
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2005-002432-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002432-10.